Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Aug 08 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Prucalopride Tablets in two dosages. Prucalopride is used to treat chronic idiopathic constipation and aids in promoting regular bowel movements. The tablets will be manufactured at Zydus's facility in Ahmedabad, and the product had significant annual sales in the United States. This filing serves to inform investors and the stock exchange about this important regulatory approval.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases